AI Article Synopsis
- * Recent advancements in immunotherapy have improved treatment options for non-small-cell lung cancer (NSCLC), but SCLC still poses significant challenges due to its aggressive nature and high chances of recurrence or metastasis.
- * The article discusses the emerging role of stereotactic radiotherapy in managing small-cell lung cancer, similar to its established use in treating early-stage NSCLC and metastatic diseases.
Article Abstract
Small-cell lung cancer is the most aggressive form of lung neoplasia, treated in recent decades with chemoradiotherapy in case of limited stage and chemotherapy alone at the metastatic stage. In the last few years, the advent of immunotherapy has changed the landscape in the treatment of non-small-cell lung cancer, and to a lesser degree in small-cell lung cancer. Despite the recent advances in research, small-cell lung cancer is still considered an aggressive and lethal disease characterized by high recurrence or metastatic potential. As stereotactic radiotherapy has established itself as the standard of care in the early stage of inoperable non-small-cell lung cancer and in metastatic disease to treat brain and extracranial metastases, these same issues now arise in the management of small-cell lung cancer. This article aims to review the current knowledge and the potential of stereotactic radiotherapy in small-cell lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canrad.2024.07.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!